SENSEX NIFTY
Jun 04, 2009, 03.19 PM IST | Source: Press Release

Anu's Laboratories recommends 1:1 bonus shares

Anu's Laboratories is in manufacturing of bulk drug intermediates for the last 13 years and having leadership in most of its products being manufactured namely i.e 2,4-Dichloro-5 Fluoro Acetophenone and other high quality intermediates such as Chlorohexanone, 1,3-Dibromo Propane, Methyl-4 (4-Chloro 1 oxo butyl), Di-Methyl Acetate etc

Anu's Laboratories recommends 1:1 bonus shares

Anu's Laboratories is in manufacturing of bulk drug intermediates for the last 13 years and having leadership in most of its products being manufactured namely i.e 2,4-Dichloro-5 Fluoro Acetophenone and other high quality intermediates such as Chlorohexanone, 1,3-Dibromo Propane, Methyl-4 (4-Chloro 1 oxo butyl), Di-Methyl Acetate etc.,

 

Company has been working on various new processes taking advantage  of its edge on process development, exploring the new export markets including regulatory markets with the coming up of new FDA plant at Vizag with outlay of Rs 63.00 crores and expanding the capacities in existing units and at other places including other states.

 

The board of directors have recommended the bonus shares in the ratio of 1: 1 i.e one bonus share for every one share held by the share holders.

 

Further, the Board of Directors have decided to take the approval from share holders for fund raising to the tune of Rs 250 crores for further expansion, acquisition of facilities and enhancement of business horizon keeping in view of the arising opportunities in Bulk drug intermediates and APIs and exploring the opportunities in organic and inorganic growth

 

Anuís laboratories Ltd is an ISO 9001:2000 certified company engaged in the manufacture of quality drug intermediates. A sick unit was acquired by Mr Haribabu and Mr Nagesh.S.Walimbe in 1996 and was named Anuís laboratories Ltd. since then, the companyís PAT has grown 25 times from Rs 5.4 million in 2003-04 to Rs 135.4 million in 2006-07. Its first product was Astrophenom, a drug intermediary.

 

Under their strategic leadership the company has grown to the current stature where it stands as market leader in the production of DCFA, occupying 60% of the market share. DCFA is an intermediate used in the production of Ciprofloxacin and has a competitive position in the production of other intermediates as well. Anuís Labs is successful in keeping Chinese competition at bay with its cost competitive and quality foothold. Also, the company strongly believed and worked towards better customer relations.

Anus Labs stock price

On October 20, 2014, Anus Laboratories closed at Rs 0.35, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 0.74 and the 52-week low was Rs 0.17.


The latest book value of the company is Rs 6.77 per share. At current value, the price-to-book value of the company was 0.05.

Set email alert for

ADS BY GOOGLE

video of the day

HDFC Bank, ICICI Bank top picks: Jitendra Sriram

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.